Crotaline snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Drug Profile

Crotaline snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Alternative Names: Anavip; Crotalidae immune F(ab)2 (equine); Crotalidae snake antivenom - Instituto Bioclon/Rare Disease Therapeutics

Latest Information Update: 15 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Instituto Bioclon
  • Developer Instituto Bioclon; Rare Disease Therapeutics
  • Class Antivenins; Fab fragments
  • Mechanism of Action Protein inhibitors; Viper venom inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Snake venom poisoning
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Snake venom poisoning

Most Recent Events

  • 08 Oct 2018 Launched for Snake venom poisoning in USA (IV)
  • 20 Jun 2005 Phase-II clinical trials in Snake venom poisoning in USA (IV) (NCT00868309)
  • 20 Jan 2004 Crotaline snake antivenom received Orphan Drug Status for Snake venom poisoning in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top